This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).
Multiple Myeloma
This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
-
Local Institution - 035, Hot Springs, Arkansas, United States, 71913
Local Institution - 641, Cerritos, California, United States, 90703-2679
Local Institution - 683, Corona, California, United States, 92879
Los Angeles Cancer Network - Fountain Valley, Fountain Valley, California, United States, 92708
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States, 90033
USC Norris Comprehensive Cancer Center, Newport, California, United States, 92663
Yale University School Of Medicine, New Haven, Connecticut, United States, 06511
Local Institution - 029, Fort Myers, Florida, United States, 33901
Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States, 32207-8432
Local Institution - 693, Ocala, Florida, United States, 34471-6950
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Celgene,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2032-06-25